13:05     SHINEWAY PHARM<02877> - Results Announcement (1)                    

    China Shineway Pharmaceutical Group Limited announced on 29/03/2005:      
    (stock code: 02877 )                                                      
    Year end date: 31/12/2004                                                 
    Currency: RMB                                                             
    Auditors' Report: Unqualified                                             
                                                                              
                                                            (Audited   )      
                                         (Audited   )       Last              
                                         Current            Corresponding     
                                         Period             Period            
                                         from 01/01/2004    from 01/01/2003   
                                         to 31/12/2004      to 31/12/2003     
                                   Note  ('000      )       ('000      )      
    Turnover                        2  : 703,575            604,042           
    Profit/(Loss) from Operations      : 280,809            185,082           
    Finance cost                       : N/A                N/A               
    Share of Profit/(Loss) of                                                 
      Associates                       : N/A                N/A               
    Share of Profit/(Loss) of                                                 
      Jointly Controlled Entities      : N/A                N/A               
    Profit/(Loss) after Tax & MI       : 260,793            151,370           
    % Change over Last Period          : +72.29    %                          
    EPS/(LPS)-Basic (in dollars)    3  : 0.42               0.25              
             -Diluted (in dollars)  3  : N/A                N/A               
    Extraordinary (ETD) Gain/(Loss)    : N/A                N/A               
    Profit/(Loss) after ETD Items      : 260,793            151,370           
    Final Dividend                     : NIL                N/A               
      per Share                                                               
    (Specify if with other             : N/A                N/A               
      options)                                                                
                                                                              
    B/C Dates for                                                             
      Final Dividend                   : N/A                                  
    Payable Date                       : N/A                                  
    B/C Dates for Annual                                                      
      General Meeting                  : 09/05/2005         to 12/05/2005 bdi.
    Other Distribution for             : N/A                                  
      Current Period                                                          
                                                                              
    B/C Dates for Other                                                       
      Distribution                     : N/A                                  
                                                                              
    Remarks:                                                                  
                                                                              
                                                                              
    (I)     Listing date and basis of presentation                            
                                                                              
    China Shineway Pharmaceutical Group Limited (the "Company") was           
    incorporated and registered as an exempted company with limited liability 
    in the Cayman Islands under the Company Law (2001 Second Revision) Chapter
    22 of the Cayman Islands on 14 August 2002 and its shares of the Company  
    were listed on the Stock Exchange of Hong Kong Limited on 4 December 2004.
                                                                              
    Under a group reorganization scheme to rationalize the structure of the   
    Group in preparation for the listing of the Company's shares on the Stock 
    Exchange, the Company became the holding company of the companies         
    comprising the Group on 10 November 2004.                                 
                                                                              
    The Group resulting from the group reorganization is regarded as a        
    continuing entity.  Accordingly, the financial statements of the Group    
    have been prepared using the principles of merger accounting.  The        
    financial statements have been prepared under the historical cost         
    convention and have been prepared in accordance with the International    
    Financial Reporting Standards.                                            
                                                                              
    (II)    An analysis of turnover from continuing operations                
                                                                              
    Turnover represents the net amount received and receivable from sales of  
    Chinese pharmaceutical products.                                          
                                                                              
    The Group's operation is regarded as a single segment, being an enterprise
    engaged in research and development, manufacture and trading of Chinese   
    pharmaceutical products. Over 90% of the Group's sales are made in the PRC
    and over 90% of the Group's assets are situated in the PRC during the     
    year.  Accordingly, no segmental analysis of the business and geographical
    segments is presented for the year.